TriSalus Life Sciences, Inc. (TLSI)
3.53
-0.10
(-2.75%)
USD |
NASDAQ |
Oct 19, 16:00
3.53
0.00 (0.00%)
After-Hours: 16:47
TriSalus Life Sciences Enterprise Value : 211.27M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 211.27M |
| October 15, 2026 | 227.87M |
| October 14, 2026 | 227.87M |
| October 13, 2026 | 234.02M |
| October 12, 2026 | 242.62M |
| October 09, 2026 | 237.70M |
| October 08, 2026 | 242.01M |
| October 07, 2026 | 249.38M |
| October 06, 2026 | 250.61M |
| October 05, 2026 | 257.37M |
| October 02, 2026 | 253.69M |
| October 01, 2026 | 243.24M |
| September 30, 2026 | 253.07M |
| September 29, 2026 | 249.38M |
| September 28, 2026 | 257.99M |
| September 25, 2026 | 254.92M |
| September 24, 2026 | 271.51M |
| September 23, 2026 | 295.49M |
| September 22, 2026 | 291.18M |
| September 21, 2026 | 294.26M |
| September 18, 2026 | 301.63M |
| September 17, 2026 | 289.34M |
| September 16, 2026 | 291.18M |
| September 15, 2026 | 281.96M |
| September 14, 2026 | 281.35M |
| Date | Value |
|---|---|
| September 11, 2026 | 274.89M |
| September 10, 2026 | 277.05M |
| September 09, 2026 | 280.73M |
| September 08, 2026 | 278.89M |
| September 04, 2026 | 295.49M |
| September 03, 2026 | 294.26M |
| September 02, 2026 | 304.09M |
| September 01, 2026 | 305.94M |
| August 31, 2026 | 292.41M |
| August 28, 2026 | 285.04M |
| August 27, 2026 | 291.18M |
| August 26, 2026 | 291.18M |
| August 25, 2026 | 297.33M |
| August 24, 2026 | 302.25M |
| August 21, 2026 | 312.08M |
| August 20, 2026 | 309.62M |
| August 19, 2026 | 325.61M |
| August 18, 2026 | 320.07M |
| August 17, 2026 | 312.08M |
| August 14, 2026 | 312.08M |
| August 13, 2026 | 334.21M |
| August 12, 2026 | 339.13M |
| August 11, 2026 | 340.97M |
| August 10, 2026 | 331.14M |
| August 07, 2026 | 332.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
| Savara, Inc. | 771.40M |
| Vericel Corp. | 1.986B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.187M |
| Revenue (Quarterly) | 11.41M |
| Total Expenses (Quarterly) | 20.59M |
| EPS Diluted (Quarterly) | -0.1576 |
| Gross Profit Margin (Quarterly) | 86.78% |
| Profit Margin (Quarterly) | -80.54% |
| Earnings Yield | -36.69% |
| Normalized Earnings Yield | -39.14 |